The number of therapeutic antibodies entering the market continues to grow annually, with 2017 seeing ten approvals in either the European Union or United States supported by a robust late-stage clinical pipeline that will likely yield even more approved drugs in 2018 and 2019. Making a drug is an expensive and time-consuming endeavor requiring an incredible level of detail and rigor to ensure that drugs are safe, efficacious, manufacturable and convenient to administer to the patient. While antibody generation is highly commoditized, with modern in vivo and in vitro libraries typically producing vast numbers of clones, the analytical tools used to characterize them at the molecular level to understand their mechanism of action often fall orders of magnitude behind in throughput. This series of articles reviews some technological advances that can help triage library-to-leads and accelerate drug discovery.
The Carterra® LSA™ is a high throughput surface plasmon resonance (SPR) instrument that can streamline the characterization of antibody libraries in terms of their binding kinetics, affinity, and epitope specificity, which are key parameters used to assess clones and select leads. The LSA analyzes up to 384 binding interactions in parallel with minimal sample consumption, making it significantly faster and more efficient than other methods.
To learn more about Carterra’s high throughput SPR capabilities, visit us online at: www.carterra-bio.com